tiprankstipranks
Trending News
More News >
Nuformix Plc (GB:NFX)
LSE:NFX

Nuformix Plc (NFX) Price & Analysis

Compare
10 Followers

NFX Stock Chart & Stats

0.23p
<0.01p(2.11%)
At close: 4:00 PM EST
0.23p
<0.01p(2.11%)

Nuformix Plc News

NFX FAQ

What was Nuformix Plc’s price range in the past 12 months?
Nuformix Plc lowest share price was 0.06p and its highest was 0.56p in the past 12 months.
    What is Nuformix Plc’s market cap?
    Nuformix Plc’s market cap is £4.01M.
      When is Nuformix Plc’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Nuformix Plc’s earnings last quarter?
      Currently, no data Available
      Is Nuformix Plc overvalued?
      According to Wall Street analysts Nuformix Plc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Nuformix Plc pay dividends?
        Nuformix Plc does not currently pay dividends.
        What is Nuformix Plc’s EPS estimate?
        Nuformix Plc’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Nuformix Plc have?
        Nuformix Plc has 2,109,750,000 shares outstanding.
          What happened to Nuformix Plc’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Nuformix Plc?
          Currently, no hedge funds are holding shares in GB:NFX
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Company Description

            Nuformix Plc

            Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.

            Nuformix Plc (NFX) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Evgen Pharma
            Futura Medical
            ImmuPharma
            OptiBiotix Health
            HemoGenyx Pharmaceuticals Plc
            Popular Stocks